Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.
Tagged patentability · clear
IN RE KILLIAN Before Taranto, Clevenger, and Chen. Appeal from the Patent Trial and Appeal Board. Summary: Section 101 jurisprudence is still sound post- Dobbs . Killian applied for a patent related to a system and method “for determining eligibility…
INTEL CORPORATION v. QUALCOMM INCORPORATED Before Prost, Taranto, and Hughes. Appeal from the Patent Trial and Appeal Board. Summary: Indefinite claims do not preclude patentability analysis at the PTAB. Intel Corp. (“Intel”) requested an inter…
No, my site did not get overrun by the pharmaceutical pushers that like to submit "advice" in the comments section. The title is referring to entity size (i.e., undiscounted, small, or micro). This posts will compare the three entity types on…
Below is an animated visualization of the subject matter eligibility 101 roller coaster that patent prosecutors and examiners have been on over the past 5 years. The visualization (interactive version available here , registration required) looks at…
Sitting en banc, a fractured Federal Circuit (Appeal no. 2015-1177 ( Fed. Cir., Oct. 4, 2017 )) released 140+ pages comprising five separate opinions (7 Judges “concur in result”). The majority held that, at least under the current PTO…
Written by Peter E. Heuser , Schwabe, Williamson & Wyatt, P.C. In almost 150 pages and five separate opinions, a majority of an en banc Circuit remands to the Board the decision in Aqua Products v. Matal , instructing the Board to issue an IPR decision…
Written by Peter E. Heuser , Schwabe, Williamson & Wyatt In Nidec v. Zhongshan , the entire panel affirms a determination of obviousness but two judges question whether § 315(c) of the AIA was improperly used to permit joinder as to a second Zhongshan…
In Regeneron Pharmaceuticals v. Merus N.V. , Appeal No. 2016-1346 (Fed. Cir., July 27, 2017), a split three-judge panel of Prost, Wallach and Newman (Newman dissenting) affirmed the district court’s ruling that claim 1 of Regeneron’s U.S. Pat.…
In the fourth of a recent series of appellate decisions establishing patent-eligibility of patent claims post-Alice, in McRO, Inc. v. Bandai Namco Games America , the Court of Appeals for the Federal Circuit reversed a district court ruling of…
Each country has its own patent system, and no authority can issue a patent enforceable in any other country. Because today’s increasingly global economy demands global cooperation to protect intellectual property rights internationally, 18 states…
Last week’s article detailed prior art and patentability , and defined prior art as all information pertinent to a patent that was publicly available before that patent’s application was submitted. This information is important because novelty…
Patents exist to promote innovation. By granting a federally recognized documents to inventors with a new idea, the government is able to make these ideas public while at the same time protecting the rights of the inventor. This free exchange of…
